Compare ATAI & LIME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATAI | LIME |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2025 | 2026 |
| Metric | ATAI | LIME |
|---|---|---|
| Price | $4.94 | $25.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $15.88 | N/A |
| AVG Volume (30 Days) | ★ 10.1M | 404.0K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,089,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1227.60 | N/A |
| 52 Week Low | $2.58 | $23.87 |
| 52 Week High | $6.73 | $26.00 |
| Indicator | ATAI | LIME |
|---|---|---|
| Relative Strength Index (RSI) | 54.59 | 60.49 |
| Support Level | $3.56 | N/A |
| Resistance Level | $5.00 | $26.00 |
| Average True Range (ATR) | 0.43 | 1.23 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 62.50 | 76.77 |
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.